Literature DB >> 1261086

Experimental cutaneous leishmaniasis. V. Protective immunity in subclinical and self-healing infection in the mouse.

P M Preston, D C Dumonde.   

Abstract

This study shows how infection of CBA mice with L. tropica can be manipulated so as to mimic the principal features of both subclinical and self-healing cutaneous leishmaniasis in man. CBA mice were infected with graded inocula of L. tropica promastigotes. The pattern of primary infection was found to be dependent on dose of infecting organisms: mice given low dose inocula (10(2), 10(3)) developed subclinical infections; those given high dose inocula (10(4), 10(5), 10(6)) developed overt, clinical lesions. Size and duration of lesions, and antibody production were directly proportional to dose; delayed hypersensitivity responses were inversely proportional to dose. Protective immunity to challenge infection was induced by both subclinical and clinical infection; and was manifest both during and after the healing stages of primary lesions. Protective immunity was also induced by artificial immunization with sonicated promastigotes in adjuvants but was only manifest if the challenge dose was not too large. The course of challenge infections differed depending on the method of immunization, i.e. whether by infection or artificial immunization. Lymphoid cells from immune CBA mice conferred protection on recipient syngeneic CBA mice against challenge infection; serum from immune mice did not, but suspension of immune peritoneal cells in immune serum enhanced their protective capacity. The experimental induction of protective immunity by low-dose infection, without a clinical allergic response at the site of inoculation, is of importance in designing an immunoprophylactic approach to human leishmaniasis.

Entities:  

Mesh:

Substances:

Year:  1976        PMID: 1261086      PMCID: PMC1538360     

Source DB:  PubMed          Journal:  Clin Exp Immunol        ISSN: 0009-9104            Impact factor:   4.330


  7 in total

1.  [Not Available].

Authors:  H FLOCH; M CASILE
Journal:  Bull Soc Pathol Exot Filiales       Date:  1955

Review 2.  Cell-mediated and humoral immunity to protozoan infections.

Authors:  J Mauel; R Behin
Journal:  Transplant Rev       Date:  1974

3.  Experimental cutaneous leishmaniasis. 3. Effects of thymectomy on the course of infection of CBA mice with Leishmania tropica.

Authors:  P M Preston; R L Carter; E Leuchars; A J Davies; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1972-02       Impact factor: 4.330

4.  Role of lymphocyte activation products (LAP) in cell-mediated immunity. II. Effects of lymphocyte activation products on lymph node architecture and evidence for peripheral release of LAP following antigenic stimulation.

Authors:  R H Kelly; R A Wolstencroft; D C Dumonde; B M Balfour
Journal:  Clin Exp Immunol       Date:  1972-01       Impact factor: 4.330

5.  Immunity in cutaneous leishmaniasis of the guinea-pig.

Authors:  A D Bryceson; R S Bray; R A Wolstencroft; D C Dumonde
Journal:  Clin Exp Immunol       Date:  1970-09       Impact factor: 4.330

Review 6.  The role of the macrophage in delayed hypersensitivity.

Authors:  D C Dumonde
Journal:  Br Med Bull       Date:  1967-01       Impact factor: 4.291

7.  The passive transfer of delayed hypersensitivity in the guinea-pig. II. The ability of passively transferred antibody to cause local inflammation and retention of antigen and the role of these phenomena in the passive transfer of delayed hypersensitivity.

Authors:  G L Asherson
Journal:  Immunology       Date:  1967-10       Impact factor: 7.397

  7 in total
  34 in total

1.  Evolution of lesion formation, parasitic load, immune response, and reservoir potential in C57BL/6 mice following high- and low-dose challenge with Leishmania major.

Authors:  R Lira; M Doherty; G Modi; D Sacks
Journal:  Infect Immun       Date:  2000-09       Impact factor: 3.441

2.  Vaccine-induced immunity against cutaneous leishmaniasis in BALB/c mice.

Authors:  D Frommel; B W Ogunkolade; I Vouldoukis; L Monjour
Journal:  Infect Immun       Date:  1988-04       Impact factor: 3.441

3.  Specific immunization of mice against Leishmania mexicana amazonensis using solubilized promastigotes.

Authors:  M Barral-Netto; S G Reed; M Sadigursky; G Sonnenfeld
Journal:  Clin Exp Immunol       Date:  1987-01       Impact factor: 4.330

4.  Suppression of pathogenesis in cutaneous leishmaniasis by UV irradiation.

Authors:  M S Giannini
Journal:  Infect Immun       Date:  1986-03       Impact factor: 3.441

5.  Intralesional plasma cells and serological responses in human cutaneous leishmaniasis.

Authors:  P L Moriearty; G Grimaldi; B Galvão-Castro; M P de Oliveira Neto; M C Marzochi
Journal:  Clin Exp Immunol       Date:  1982-01       Impact factor: 4.330

6.  Mechanisms associated with immunoregulation in human American cutaneous leishmaniasis.

Authors:  M Castés; A Agnelli; A J Rondón
Journal:  Clin Exp Immunol       Date:  1984-08       Impact factor: 4.330

7.  Relationship between delayed hypersensitivity response and acquired cell-mediated immunity in C57BL/6J mice infected with Leishmania donovani.

Authors:  J R Fahey; R Herman
Journal:  Infect Immun       Date:  1985-08       Impact factor: 3.441

8.  Coinjection with CpG-containing immunostimulatory oligodeoxynucleotides reduces the pathogenicity of a live vaccine against cutaneous Leishmaniasis but maintains its potency and durability.

Authors:  Susana Mendez; Khaled Tabbara; Yasmine Belkaid; Sylvie Bertholet; Daniela Verthelyi; Dennis Klinman; Robert A Seder; David L Sacks
Journal:  Infect Immun       Date:  2003-09       Impact factor: 3.441

9.  Experimental murine candidiasis: pathological and immune responses to cutaneous inoculation with Candida albicans.

Authors:  D K Giger; J E Domer; J T McQuitty
Journal:  Infect Immun       Date:  1978-02       Impact factor: 3.441

10.  Persistence of virulent Leishmania major in murine cutaneous leishmaniasis: a possible hazard for the host.

Authors:  T Aebischer; S F Moody; E Handman
Journal:  Infect Immun       Date:  1993-01       Impact factor: 3.441

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.